Answers are grounded in this paper and cite their sources.
Observational analysis evaluates diagnostic accuracy of plasma phosphorylated tau in Alzheimer's Disease, suggesting its utility in screening.
Plasma biomarkers have emerged as promising less invasive alternatives for Alzheimer's disease (AD) detection. However, the diagnostic performance of phosphorylated tau (p‐tau) isoforms remains incompletely validated. In a cohort of 160 patients from a memory clinic, plasma levels of p‐tau217, p‐tau212, p‐tau181, p‐tau231, and BD‐tau were measured using Single Molecule Array (Simoa) in‐house assays, alongside NFL and GFAP. Subjects were classified using the Erlangen Score into Controls ( n = 53), neurochemically possible AD ( n = 27), and probable AD ( n = 80). Plasma concentrations of all p‐tau isoforms were significantly elevated in both Possible AD and Probable AD groups compared to Controls ( p < 0.001). Notably, p‐tau217 exhibited the highest diagnostic accuracy (AUC = 0.954) and correlated with CSF classical biomarkers. A positive result for p‐tau217 increases the probability of AD almost fivefold. Plasma p‐tau217 reflects AD neurochemical changes and has high negative predictive value, supporting its use as a screening tool. However, moderate PPV suggests the need for confirmatory testing to ensure an accurate diagnosis.
No takes yet. Share an insight, caveat, or question.
Dulewicz et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: